Skip to content
Peptide Atlas
All peptides

MOTS-c

Tier 2 · Preclinical
Also known as MOTSc · Mitochondrial ORF of the 12S rRNA type-c

The strongest human evidence is CohBar's Phase 1a/1b randomized, double-blind, placebo-controlled study1 — but it tested CB4211, a MOTS-c analog rather than native MOTS-c, with a small Phase 1b treatment group (n=11 vs n=9 placebo; total enrollment 88). A Phase 2a study in prediabetes/overweight adults is described as recruiting18. Beyond this, essentially all efficacy findings come from animal models, in vitro work, human observational associations, expert opinion and one 2025 preprint22. Multiple sources state there are no patient trials with native MOTS-c and that no clinical application method has been developed11,20. Some specific quantitative figures originate from a single tier-3 clinic analysis and are not corroborated by higher-tier sources.

Half-life
Not recorded
Routes
Subcutaneous injection (human protocols, src-2, src-9, src-16) · Intraperitoneal injection (animal studies, src-4, src-25) · Intracerebroventricular / carrier-coupled intranasal (animal cognition studies, src-12)
Goals
Metabolic health / insulin sensitivity · Weight / fat loss · Exercise performance and recovery · Longevity / healthy aging
Cost / mg
Not recorded

How it works

MOTS-c is a small 16-amino-acid peptide that, according to vendor and review sources, is encoded inside mitochondrial DNA and was discovered in 2015(vendor claim). Several sources describe it as a 'mitokine' — a signal that reports on mitochondrial health. Its most studied action, per multiple sources, is switching on AMPK, a cellular energy sensor that tells cells to burn fuel more efficiently, become more sensitive to insulin, and resist storing energy as fat. Under stress (low glucose, oxidative stress) sources report the peptide moves into the cell nucleus and turns on antioxidant and adaptive stress-response genes. Because exercise naturally raises MOTS-c and the peptide reproduces several exercise-like effects in animals, sources frequently describe it as an 'exercise-mimetic.'

Overview

What MOTS-c is

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is described across sources as a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene. A clinic press article18 states it was first described in 2015 by researchers at the USC Leonard Davis School of Gerontology with collaborators at UCLA and the NIH. A peptide blog reports it was first characterized in 2015 by Lee and colleagues, who showed stressed muscle cells release it so it can translocate to the nucleus and upregulate adaptive stress-resistance genes (sequence M-R-W-Q-Q-T-G-I-F-S-M-S-G-W-L-P)(vendor claim). The ADDF review17 gives its formula as C101H152N28O22S2 (MW 2174.6 g/mol). A 2025 study6 reports it is widely expressed across tissues (brain, heart, liver, muscle, testis, kidney, gut and plasma) in rodents and humans.

Several sources characterize MOTS-c as a 'mitokine' that reports mitochondrial health and, according to a pharmacy blog, orchestrates systemic responses via AMPK activation(vendor claim). Health.com20 describes it as an injectable peptide meant to mimic the effects of exercise, and a 2022 review12 calls it the mitochondrial-derived peptide most associated with exercise, noting its expression increases in skeletal muscle, systemic circulation and the hypothalamus upon exercise. A 2021 review14 describes it as an exercise-sensitive myokine with exercise-mimetic properties.

What the human evidence shows

Human evidence is very limited and largely derives from a MOTS-c analog, not native MOTS-c. CohBar reports1 that its Phase 1a/1b study of CB4211 — Phase 1a being a double-blind, placebo-controlled single- and multiple-ascending-dose safety/PK assessment, and Phase 1b a randomized, double-blind, placebo-controlled evaluation of one dose given once daily for four weeks in obese subjects with NAFLD — enrolled 88 total (11 CB4211, 9 placebo) and ran from July 2018 to April 2021. CohBar reports the 25 mg once-daily dose produced a 21% ALT reduction from baseline versus 4% placebo and a 28% AST reduction versus 11% placebo (p<0.05), a 6% glucose reduction versus 0% placebo (p<0.05), and a trend toward lower body weight. However, CohBar also reports the liver-fat responder rate (36% for >30% relative reduction) was only marginally above placebo (33%), with similar absolute liver-fat reductions (5.03% vs 4.88%). A clinic analysis summarizes this as the only small human trial (20 subjects, CB4211, an analog rather than native MOTS-c)(vendor claim). A clinic press article18 states a Phase 2a study in adults with prediabetes and overweight/obesity is recruiting. Multiple sources11,20 emphasize there are no patient trials with native MOTS-c, that human observational samples are under 30 and not placebo-controlled at definitive scale, and that no clinical application method has been developed.

Human observational data include reports6,23 that MOTS-c expression is decreased in type 2 diabetes patients and declines with age (one source states 21% lower in 70-81 year-olds and notes Japanese centenarians harbor beneficial variants), that Health.com20 links lower MOTS-c levels to components of metabolic syndrome, and that a 2024 study8 found reduced serum and tumor MOTS-c in ovarian cancer patients associated with poor prognosis. A 2025 study7 reports serum MOTS-c increments within 24 hours post-cardiopulmonary bypass predicted ARDS incidence (AUC=0.885). A clinic analysis states exercise increases endogenous muscle MOTS-c 12-fold — a figure from a single low-tier source.

What the preclinical evidence shows

Animal and in vitro findings dominate. The 2015 study4 reports MOTS-c prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice. A vendor resource states that in high-fat-diet mice MOTS-c improves insulin sensitivity, reduces fat mass and prevents obesity, with replication by multiple groups(vendor claim). One source6 reports intraperitoneal MOTS-c in fed mice reduced blood glucose and visceral fat similarly to aerobic exercise, and in vitro increased fatty acid utilization. Additional animal/in vitro findings include improved T2DM-induced liver fibrosis via a Keap1-Nrf2-Smad2/3 mechanism6, alleviation of gestational-diabetes hyperglycemia and β-cell protection13, prevention of muscle atrophy and myostatin reduction (~40%, p<0.05) via a CK2-PTEN-mTORC2-AKT-FOXO1 pathway, anti-tumor effects on ovarian cancer without systemic toxicity8, endothelial protection in lung ischemia-reperfusion injury7, and improved exercise capacity in young and aged mice14. A clinic analysis cites 12-15% single-dose performance gains and 100% vs 16.6% treadmill completion, and 6-7% lifespan trends — figures from a single low-tier source.

Mechanistically, sources converge on AMPK activation4,17 with nuclear translocation under stress engaging NRF2/antioxidant gene programs7,16. Cognitive effects are delivery-dependent: the ADDF review17 reports peripheral MOTS-c had no cognitive effect in mice and that MOTS-c is not blood-brain-barrier penetrant, with memory protection seen only via intracerebroventricular or carrier-coupled intranasal delivery.

Proposed and investigational uses

Health.com20 states MOTS-c is being evaluated for obesity and osteoporosis and is mainly studied for metabolism, insulin resistance and slower aging. Innerbody describes it as a peptide that may help extend lifespan and improve metabolism while maintaining muscle and losing fat(vendor claim). A 2025 preprint22 proposes MOTS-c for ME/CFS on a mitochondrial-dysfunction rationale but itself states human safety and efficacy data are lacking. Review sources also raise theoretical roles in retinal disease/AMD2,24. These remain investigational — a 2023 review11 states no effective method of clinical application has been developed.

What the research shows

184 findings extracted from the 25 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 9 human trial findings, 9 human study findings, 21 animal findings and 5 expert opinion findings.

  • human trialCB4211 demonstrated robust and significant reductions in Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) biomarkers of liver damage1

  • human trialCB4211 demonstrated significant decrease in glucose levels1

  • human trialCB4211 showed a trend towards lower body weight after four weeks of treatment1

  • human trialCB4211 25 mg dose showed 21% reduction in ALT from baseline compared to 4% in placebo1

  • human trialCB4211 25 mg dose showed 28% reduction in AST from baseline compared to 11% in placebo (p<0.05)1

  • human trialCB4211 showed 6% reduction in glucose from baseline compared to 0% in placebo (p<0.05)1

  • human trialCB4211 achieved 36% responder rate for >30% relative reduction in liver fat content compared to 33% in placebo1

  • human trialCB4211 was tested in Phase 1a/1b (n=88)17

Show 36 more findings

  • human trialA recruiting Phase 2a study is evaluating investigational MOTS-c in adults with prediabetes and overweight or obesity, with insulin sensitivity, metabolic markers, body weight, waist circumference, and safety among the study's measured outcomes18

  • human studyMitochondrial-Derived Peptides (MDPs) have a cytoprotective role in several diseases, including AMD2

  • human studyIn clinical studies, the expression of MOTS-c is decreased in T2DM patients6

  • human studySerum MOTS-c increments within 24 hours post-cardiopulmonary bypass (ΔMOTS-c) predicted ARDS incidence with multivariate models incorporating ΔMOTS-c achieving AUC = 0.8857

  • human studyMOTS-c levels are reduced in both serum and tumor tissues from ovarian cancer patients8

  • human studyReduced MOTS-c levels are associated with poor patient prognosis in ovarian cancer8

  • human studyAcute high intensity exercise in humans can increase concentrations of MOTS-c in skeletal muscle and plasma14

  • human studyEndogenous levels decline with age17

  • human studyEndogenous MOTS-c levels decline with age and in populations with metabolic dysfunction17

  • human studyHuman observational studies have found a link between lower MOTS-c levels and components of metabolic syndrome, like obesity and insulin resistance20

  • animalMOTS-c improves insulin sensitivity in mouse models of type 2 diabetes3

  • animalMOTS-c treatment in mice prevented age-dependent insulin resistance4

  • animalMOTS-c treatment in mice prevented high-fat-diet-induced insulin resistance4

  • animalMOTS-c treatment in mice prevented diet-induced obesity4

  • animalMOTS-c has been shown to improve glucose metabolism in skeletal muscle5

  • animalIntraperitoneal injection of MOTS-c in fed mice significantly reduced blood glucose level and visceral fat with results similar to aerobic exercise6

  • animalMOTS-c and aerobic exercise therapy improved T2DM-induced liver fibrosis in a rat model6

  • animalIn HFD-induced T2DM mice, the TGF-β1/Smad pathway is activated and liver fibrosis is obvious6

  • animalIn a rat model, MOTS-c can inhibit T2DM and reduce oxidative stress and liver fibrosis6

  • animalMOTS-c can modulate antioxidant defence mechanisms during aerobic exercise to reduce diabetic myocardial damage in rat heart tissue6

  • animalMOTS-c has been shown to improve glucose metabolism in skeletal muscle11

  • animalMOTS-c can be an effective treatment for GDM13

  • animalMOTS-c significantly alleviated hyperglycemia in GDM mice13

  • animalMOTS-c improved insulin sensitivity and glucose tolerance in GDM mice13

  • animalMOTS-c reduced birth weight and the death of offspring induced by GDM in mice13

  • animalMOTS-c rejuvenates aging phenotypes in muscle in mice17

  • animalPeripherally administered MOTS-c had no effect on cognition in mice at a dose that improved physical capacity17

  • animalCentrally administered MOTS-c reduces inflammation-based memory problems in mice17

  • animalMOTS-c protects against Aβ42 and LPS-induced memory impairment on novel object recognition and object location recognition tasks in mice17

  • animalIn mouse studies, MOTS-c helped prevent insulin resistance and obesity20

  • animalPreclinical evidence suggests that MOTS-c improves glucose metabolism, increases mitochondrial density, and enhances fatigue resistance22

  • expert opinionSystemic MOTS-c administration increases exercise performance by boosting skeletal muscle stress responses12

  • expert opinionSystemic MOTS-c administration enhances metabolic adaptation to exercise12

  • expert opinionThere have been no patient trials with MOTS-c20

  • expert opinionMany unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models21

  • expert opinionMOTS-c has the ability to revive oxidatively stressed RPE cells with a significant protective role24

How it works

Based on 4 human trial findings, 1 human study finding, 17 animal findings, 22 in vitro findings, 23 expert opinion findings and 21 theoretical findings.

  • human trialPhase 1a stage was a double blind, placebo-controlled single ascending dose and multiple ascending dose assessment of safety, tolerability, and pharmacokinetics1

  • human trialMOTS-c is a 16-amino-acid peptide encoded by a short open reading frame (sORF) within the mitochondrial 12S rRNA4

  • human trialThe primary target organ of MOTS-c appears to be skeletal muscle4

  • human trialMOTS-c cellular actions inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation4

  • human studyMitochondrial dysfunction contributes significantly to the etiology and pathogenesis of Age-related Macular Degeneration (AMD)2

  • animalMOTS-c exacerbates the senescence-associated-secretory-phenotype (SASP) in senescent cells by stimulating the secretion of IL-6, IL-1β, IL-8, IL-10 and tumor necrosis factor α3

  • animalMOTS-c is widely distributed and expressed in various tissues (brain, heart, liver, muscle, testis, kidney, gut, and plasma) in rodents and humans6

  • animalThe Keap1-Nrf2 pathway is activated by high levels of ROS, aerobic exercise or MOTS-c in T2DM6

Show 80 more findings

  • animalMOTS-c modulates the progression of T2DM complicated by liver fibrosis through a Keap1-Nrf2-Smad2/3 signaling pathway-dependent mechanism6

  • animalMOTS-c is a mitochondrial-derived peptide that acts as a regulator of mitochondrial-nuclear communication7

  • animalMOTS-c mediates endothelial protection against lung ischemia-reperfusion injury (LIRI) through MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes7

  • animalIn rat LIRI models, endothelial cells exhibited the most significant MOTS-c upregulation, correlating with barrier preservation and reduced oxidative stress7

  • animalHypoxia-reoxygenation triggers ROS-dependent phosphorylation of MYH9 at Ser1943 via casein kinase II subunit alpha (CK2A), enabling MOTS-c binding to MYH9-γ-Actin complexes for nuclear transport7

  • animalMOTS-c directly interacts with promoters of antioxidant genes (HMOX1, NQO1) which harbor antioxidant response elements (AREs)7

  • animalMOTS-c regulates the expression of genes such as GLUT4, STAT3, and IL-1010

  • animalMOTS-c is a mitochondrial-derived peptide that can target skeletal muscle and enhance glucose metabolism13

  • animalMOTS-c can activate insulin sensitivity in the skeletal muscle of GDM mice13

  • animalMOTS-c protects pancreatic β-cell from STZ-mediated injury13

  • animalMOTS-c treatment increases antioxidant capacity in mice14

  • animalMOTS-c has exercise mimetic properties14

  • animalExercise and MOTS-c evoke metabolic benefits through distinct and overlapping pathways14

  • animalThe protective effects involve the activation of AMPK signaling and the inhibition of pro-inflammatory cytokines17

  • in vitroHEK293 cells stably overexpressing MOTS-c had significantly reduced long-chain fatty acids and increased fatty acid utilization compared with normal HEK293 cells6

  • in vitroMOTS-c overexpression or MOTS-c addition to culture medium inhibited ROS levels6

  • in vitroMOTS-c overexpression or MOTS-c addition to culture medium increased mRNA and protein expression of Keap1-Nrf2 pathway genes6

  • in vitroMOTS-c overexpression or MOTS-c addition to culture medium decreased expression of TGF-β1/Smad pathway genes6

  • in vitroExogenous MOTS-c inhibits the proliferation of ovarian cancer cells8

  • in vitroExogenous MOTS-c inhibits migration and invasion of ovarian cancer cells8

  • in vitroExogenous MOTS-c induces cell cycle arrest in ovarian cancer cells8

  • in vitroExogenous MOTS-c induces apoptosis in ovarian cancer cells8

  • in vitroMOTS-c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation8

  • in vitroUSP7 was identified as a deubiquitinase of LARS18

  • in vitroMOTS-c attenuates USP7-mediated LARS1 deubiquitination by competing with USP7 for binding to LARS18

  • in vitroLARS1 is increased in ovarian cancer and plays an important oncogenic function8

  • in vitroMOTS-c is co-expressed with mitochondria in different tissues11

  • in vitroMOTS-c can elevate glucose uptake in vitro13

  • in vitroMOTS-c is a peptide encoded in the mitochondrial genome16

  • in vitroMOTS-c translocates to the nucleus and regulates nuclear gene expression following metabolic stress16

  • in vitroMOTS-c regulates nuclear gene expression in a 5'-adenosine monophosphate-activated protein kinase (AMPK)-dependent manner16

  • in vitroMOTS-c regulated a broad range of genes in response to glucose restriction16

  • in vitroMOTS-c regulated genes with antioxidant response elements (ARE)16

  • in vitroMOTS-c interacted with ARE-regulating stress-responsive transcription factors, such as nuclear factor erythroid 2-related factor 2 (NFE2L2/NRF2)16

  • in vitroMOTS-c acts as a metabolic regulator primarily through activation of the AMP-activated kinase (AMPK), leading to an increase in lipid metabolism and cellular glucose flux17

  • in vitroSkeletal muscle is the primary target organ of MOTS-c17

  • expert opinionMOTS-c is a signal molecule encoded by mitochondrial DNA that was discovered in 2015 and contains 16 amino acids6

  • expert opinionMOTS-c is related to the metabolic regulation of insulin6

  • expert opinionMOTS-c is located mainly in mitochondria in the resting state and is then transferred to the nucleus under the induction of oxidative stress6

  • expert opinionMOTS-c can interact with Nrf2 and participate in antioxidative stress6

  • expert opinionMOTS-c is a mitochondria-derived peptide (MDP) encoded by mitochondrial DNA12

  • expert opinionMOTS-c expression levels increase in skeletal muscles, systemic circulation, and the hypothalamus upon exercise12

  • expert opinionExogenous MOTS-c stimulates thermogenesis in subcutaneous white adipose tissues12

  • expert opinionLow levels of mitochondrial stress are beneficial for organismal health and survival through mitohormesis12

  • expert opinionMOTS-c may be an exercise-sensitive myokine14

  • expert opinionMOTS-c promotes metabolic flexibility and insulin sensitivity17

  • expert opinionMOTS-c may have anti-inflammatory properties and promote cellular energetics17

  • expert opinionTheir original research identified MOTS-c as a mitochondrial-derived peptide involved in metabolic signaling, insulin sensitivity, and metabolic homeostasis in preclinical models18

  • expert opinionMOTS-c is a naturally occurring mitochondrial-derived peptide encoded within mitochondrial DNA18

  • expert opinionResearchers have studied its relationship to skeletal muscle, insulin sensitivity, exercise signaling, metabolic homeostasis, and age-related physical decline, although much of the evidence remains preclinical18

  • expert opinionMOTS-c is an injectable peptide derived from mitochondrial DNA20

  • expert opinionMOTS-c is meant to mimic the effects of exercise20

  • expert opinionEmerging research points to mitochondrial dysfunction as a core contributor to ME/CFS pathology, marked by impaired ATP production, oxidative stress, and bioenergetic failure22

  • expert opinionMOTS-c enhances mitochondrial biogenesis, reduces oxidative damage, and modulates inflammatory responses through AMPK and NRF2 activation22

  • expert opinionDrug hypersensitivity in ME/CFS is thought to stem from underlying mitochondrial dysfunction, altered detoxification pathways, and potential polymorphisms in cytochrome P450 enzymes22

  • expert opinionMOTS-c contributes to browning of white adipose tissue23

  • expert opinionMOTS-c is the most unearthed peptide encoded by mitochondrial DNA (mtDNA)24

  • expert opinionMOTS-c is an important regulator of the nuclear genome during times of stress24

  • expert opinionMOTS-c promotes an adaptive stress response to maintain cellular homeostasis24

  • theoreticalMDPs are encoded within the mtDNA and serve as signals for organism cytoprotection and energy regulation2

  • theoreticalMDPs encoded from the 16S rRNA region of the mtDNA include Humanin and SHL2

  • theoreticalThe human mitochondrial genome is ~16.5 kilobases, circular, double-stranded, and consists of 37 genes that code for 13 proteins of the respiratory chain complexes2

  • theoreticalThe 16S rRNA gene is 1559 bp long, spanning 1671-3229 bp of the mtDNA; it occupies 1/10 of the entire mtDNA and carries ORFs that encode mitochondrial-derived peptides2

  • theoreticalMOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA that plays a cytoprotective role by helping preserve mitochondrial function and cell viability under stressful conditions3

  • theoreticalMOTS-c is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome5

  • theoreticalThe MOTS-c protein is transferred to the nucleus during metabolic stress and directs the expression of nuclear genes to promote cell balance5

  • theoreticalMOTS-c is a short peptide derived from the 12S rRNA of mitochondrial DNA8

  • theoreticalMOTS-c has been suggested as a retrograde mitochondrial signal8

  • theoreticalMOTS-c is expressed from the mitochondrial open reading frame of the 12S ribosomal RNA type-c9

  • theoreticalMOTS-c is associated with regulation of cellular metabolism and insulin action in age-related diseases9

  • theoreticalMOTS-c is a mitochondrial-derived peptide encoded by short open reading frames in the mitochondrial genome10

  • theoreticalMOTS-c has regulatory effects on mitochondrial functions, gene expression, and metabolic homeostasis10

  • theoreticalMOTS-c plays physiological functions mainly through activating the AICAR-AMPK signaling pathways by disrupting the folate-methionine cycle in cells10

  • theoreticalMOTS-c is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome11

  • theoreticalMOTS-c protein is transferred to the nucleus during metabolic stress and directs the expression of nuclear genes to promote cell balance11

  • theoreticalMOTS-c is a peptide encoded within the mitochondrial 12S ribosomal RNA gene15

  • theoreticalMOTS-c can translocate to the nucleus upon metabolic stress (e.g., glucose restriction and oxidative stress)15

  • theoreticalMOTS-c directly regulates adaptive nuclear gene expression to promote cellular homeostasis15

  • theoreticalThe mitochondrial and nuclear genomes co-evolved to independently encode for factors to cross-regulate each other16

  • theoreticalMOTS-c is a 16 amino acid mitochondrial derived peptide encoded by a short open reading frame within 12S rRNA located in the mitochondrial genome17

Dosing

Based on 1 human trial finding and 1 animal finding.

  • human trialPhase 1b was a randomized, double-blind, placebo-controlled evaluation of one dose level of CB4211 given once a day for four weeks in obese subjects with NAFLD1

  • animalBenefits were only seen when MOTS-c was administered centrally (intracerebroventricularly) or intranasally when coupled to a cell-penetrating carrier17

How the body handles it

Based on 1 human study finding, 1 animal finding and 1 in vitro finding.

  • human studyMOTS-c is present in plasma but its level decreases with age11

  • animalDifferent tissues co-expressed the protein with mitochondria, and plasma also contained the protein, but its level decreased with age5

  • in vitroMOTS-c is not BBB penetrant17

Safety and side effects

Based on 2 human trial findings, 1 animal finding and 8 expert opinion findings.

  • human trialCB4211 was well-tolerated and appeared safe with no serious adverse events in Phase 1a/1b study1

  • human trialCB4211 was safe in a short-term study, but persistent injection site reactions were common17

  • animalMOTS-c displays anti-tumor effect on ovarian cancer growth without systemic toxicity in vivo8

  • expert opinionNo effective method of applying MOTS-c in the clinic has been developed11

  • expert opinionMOTS-c therapeutic safety has not been established17

  • expert opinionMOTS-c may interact with other drugs that target AMPK17

  • expert opinionMOTS-c is not FDA-approved for weight loss, obesity, insulin resistance, energy, exercise performance, or another medical or wellness purpose18

  • expert opinionRigorous human safety data are scarce for unapproved peptides like MOTS-C21

Show 3 more findings

  • expert opinionThere is potential for serious harm to patients from unapproved peptides21

  • expert opinionSafety and efficacy data in humans are lacking for MOTS-c22

  • expert opinionME/CFS patients often experience heightened drug sensitivities and paradoxical reactions that can worsen symptoms22

What people use it for

Based on 1 human trial finding, 6 animal findings, 14 expert opinion findings and 13 theoretical findings.

  • human trialMOTS-c regulates insulin sensitivity and metabolic homeostasis4

  • animalMOTS-c has benefits for diseases such as diabetes, obesity, and aging5

  • animalMOTS-c may treat oxidative stress-induced myocardial ultrastructure damage and cardiac dysfunction by activating the Keap1-Nrf2 signalling pathway6

  • animalExogenous MOTS-c administration in rats attenuated lung injury by reducing oxidative damage, inflammation, and mortality7

  • animalMOTS-c treatment of young and aged mice improves exercise capacity/performance14

  • animalMOTS-c treatment leads to weight loss in mice14

  • animalMOTS-c treatment improves insulin sensitivity in mice14

  • expert opinionMDPs merit consideration as therapeutic targets for AMD2

Show 26 more findings

  • expert opinionMOTS-c is regarded as a sport-mimicking substance6

  • expert opinionMOTS-c is the most associated mitochondria-derived peptide with exercise12

  • expert opinionMOTS-c enhances energy expenditure and contributes to anti-obesity effects of exercise training12

  • expert opinionMOTS-c enhances metabolic flexibility, improves insulin sensitivity, and may act as an exercise mimetic17

  • expert opinionMOTS-c is being evaluated for the treatment of obesity and osteoporosis20

  • expert opinionMOTS-c is mainly studied for metabolism support, insulin resistance, and slower aging20

  • expert opinionMOTS-C (mitochondrial ORF of the 12S rRNA type-c) is a peptide marketed direct to patients21

  • expert opinionMOTS-C operates in a parallel gray market of unapproved compounds largely outside of regulatory oversight21

  • expert opinionMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is characterized by profound fatigue, post-exertional malaise (PEM), and a constellation of immune, neurological, and autonomic symptoms22

  • expert opinionMOTS-c is a mitochondrial-derived peptide with roles in increasing muscle mass23

  • expert opinionMOTS-c improves systemic metabolic function23

  • expert opinionMitochondrial damage and dysfunction have been linked to aging and accelerated cell death associated with many types of retinal degenerations24

  • expert opinionMOTS-c has untapped potential as a treatment for glaucoma, diabetic retinopathy, and age-related macular degeneration24

  • theoreticalMOTS-c is hypothesized to have antiaging activity based on correlative studies3

  • theoreticalMOTS-c can be applied in the treatment of aging, cardiovascular disease, insulin resistance, and inflammation5

  • theoreticalMOTS-c is associated with regulation of cellular metabolism and insulin action in type 2 diabetes mellitus9

  • theoreticalMOTS-c research has relevance to both type 1 and type 2 diabetes9

  • theoreticalMOTS-c could reduce insulin resistance10

  • theoreticalMOTS-c could prevent obesity10

  • theoreticalMOTS-c could improve muscle function10

  • theoreticalMOTS-c could promote bone metabolism10

  • theoreticalMOTS-c could enhance immune regulation10

  • theoreticalMOTS-c could postpone aging10

  • theoreticalMOTS-c indicates benefits for diseases such as diabetes, obesity, and aging11

  • theoreticalMOTS-c has therapeutic potential for aging, cardiovascular disease, insulin resistance, and inflammation11

  • theoreticalMOTS-c has metabolic functions15

Other findings

Based on 2 expert opinion findings.

  • expert opinionMOTS-c was first described in 2015 by researchers at the USC Leonard Davis School of Gerontology working with collaborators from UCLA and the National Institutes of Health18

  • expert opinionMOTS-c received a favorable 7-5 recommendation, with two abstentions, from the FDA's Pharmacy Compounding Advisory Committee concerning potential inclusion of MOTS-c-related substances on the 503A Bulks List18

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Human evidence is extremely thin and largely from a MOTS-c analog, not native MOTS-c

The only human clinical trial is CohBar's Phase 1a/1b study of CB4211, a MOTS-c analog rather than native MOTS-c, with a small Phase 1b treatment group (n=11 vs n=9 placebo, total enrollment 88). Multiple sources (MOTS-C: Evidence, Legality and How to Approach It — PeptideClarity, FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns, MOTS-c Peptide Dosing Guide: Protocol, Reconstitution & Metabolism (2026), MOTS-C Peptide: Separating Science from Hype | adjust.clinic, MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.) state there are no patient trials with native MOTS-c, human sample sizes are under 30 and none placebo-controlled at definitive scale, and no method of clinical application has been developed. A Phase 2a study in prediabetes/obesity is only recruiting (California Gave the World MOTS-c. Now California Trim Clinic Is Bringing the Conversation Home – News Radio KOTA).

Limited evidence

Nearly all efficacy findings are from animal or in vitro models

Insulin sensitivity, exercise performance, anti-obesity, liver fibrosis, GDM, cancer, lung injury and lifespan findings come from mouse/rat models or cell cultures. Human exercise-capacity data is described as essentially absent (MOTS-C: Evidence, Legality and How to Approach It — PeptideClarity) and safety/efficacy in humans as lacking (Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.).

Single source

CB4211 liver-fat responder rate barely exceeded placebo

CohBar's own trial report shows the headline liver-fat responder rate (36% for >30% relative reduction) was only marginally above placebo (33%), and absolute liver fat reduction was similar (5.03% vs 4.88%), even though ALT/AST and glucose reductions were statistically significant versus placebo. This nuance comes from a single company source.

Contested

Sources give differing dose ranges that don't reconcile

Practical protocols cite 5–10 mg total per injection 2–3x weekly (MOTS-C: Evidence, Legality and How to Approach It — PeptideClarity, MOTS-c Peptide Dosing Guide: Protocol, Reconstitution & Metabolism (2026), MOTS-C Peptide: Separating Science from Hype | adjust.clinic), while animal research uses 5 mg/kg daily (roughly 350 mg extrapolated to a 70 kg human) (MOTS-C Peptide: Separating Science from Hype | adjust.clinic). CohBar's human trial used 25 mg once daily of the CB4211 analog (Nonalcoholic Fatty Liver Disease Clinical Trial). These are large discrepancies and the low doses have not been validated in published human trials.

Contested

MOTS-c effect on inflammation/senescence is mixed across sources

Most sources describe MOTS-c as anti-inflammatory and antioxidant (Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c, MOTS-C Peptide: Benefits, Mechanism, Safety, and Research, MOTS-c, The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.), yet a tier-1 2018 review reports it exacerbates the senescence-associated secretory phenotype by stimulating pro-inflammatory cytokine secretion (IL-6, IL-1β, IL-8, TNFα) in senescent cells (Mitochondrial-Derived Peptides Exacerbate Senescence.).

Limited evidence

Cognitive benefits only occur with central/intranasal delivery; MOTS-c is not BBB-penetrant

The ADDF review notes MOTS-c is not blood-brain-barrier penetrant, peripheral administration had no cognitive effect in mice, and memory protection was seen only with intracerebroventricular or carrier-coupled intranasal delivery.

Preprint

ME/CFS application rests on a preprint

The proposed use of MOTS-c for ME/CFS comes from a 2025 preprint (Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c) that itself states human safety and efficacy data are lacking and warns of heightened drug sensitivities in ME/CFS patients.

Other

Not FDA-approved; regulatory status in flux and banned in sport

Multiple sources note MOTS-c is not FDA-approved for any purpose, was removed from FDA Category 2 effective April 22, 2026 but not added to the 503A Bulks List, received a split 7-5 FDA advisory vote with two abstentions, is banned by WADA at all times, and is sold in a gray market with potential for serious harm.

Single source

Many specific figures come from a single low-tier source

Figures such as 12-15% single-dose performance gains, 100% vs 16.6% treadmill completion, 12-fold exercise-induced increase, 21% lower levels in 70-81 year-olds, 6-7% lifespan improvement and ~40% myostatin reduction all originate from a single tier-3 clinic analysis website (MOTS-C Peptide: Separating Science from Hype | adjust.clinic) and are not independently corroborated in the higher-tier sources.

Single source

Claims that small human studies have proven MOTS-c improves blood sugar are not supported — the only controlled human trials used a modified analog, not MOTS-c itself.

One vendor-published source states that small clinical studies in adults with insulin resistance or prediabetes showed improved glucose tolerance and metabolic markers after 8–12 weeks of MOTS-c administration. No such interventional trials of the natural peptide appear in the medical literature. The only controlled human trial (CohBar's Phase 1a/1b) tested CB4211, a MOTS-c analog rather than MOTS-c itself, and independent reviews — as well as other statements on the same vendor page — say there have been no patient trials with native MOTS-c and that no method of clinical application has been developed.

Using it with other compounds

Check a stack
  • SS-31Complementary

    No documented conflict

    Both aim to protect and improve mitochondria but by different routes: MOTS-c works upstream through AMPK activation and Nrf2/ARE antioxidant gene expression, while SS-31 physically stabilizes cardiolipin and the electron-transport-chain supercomplexes to reduce ROS at the source. These are non-overlapping mechanisms converging on the same goal of better mitochondrial function and lower oxidative stress, making them a plausibly synergistic pairing.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory

  • TesamorelinComplementary

    No documented conflict

    Both reduce adiposity, especially visceral and hepatic fat, but through unrelated mechanisms: tesamorelin raises GH/IGF-1 to drive lipolysis, while MOTS-c acts through AMPK-driven metabolism and adipose browning. These non-overlapping fat-loss pathways can complement each other for body-composition goals.

    Tier 4Theoretical — not established

    Shares lipolysis

  • TirzepatideSame downstream effect

    Worth caution

    Tirzepatide (dual GIP/GLP-1 agonist) and MOTS-c both improve insulin sensitivity and reduce fat mass, but through entirely different mechanisms — incretin receptor signaling versus AMPK-driven muscle glucose uptake and fat oxidation. Convergent metabolic output makes them theoretically complementary.

    Tier 4Theoretical — not established
    What the research doesn't establish
    MOTS-c and tirzepatide act through separate molecular pathways — AMPK activation and muscle mitochondrial signaling for MOTS-c, versus GIP/GLP-1 receptor signaling for tirzepatide — and their overlap is only at the level of shared endpoints such as improved insulin sensitivity and reduced fat mass. That they are complementary, rather than additive, redundant or counterproductive when combined, has not been demonstrated.
  • SemaglutideComplementary

    No documented conflict

    Both improve glucose handling and drive fat loss but by entirely different mechanisms: semaglutide is a GLP-1 receptor agonist acting on insulin/glucagon and appetite, while MOTS-c works intracellularly via AMPK and improved mitochondrial/glucose metabolism. Combining a central/hormonal metabolic driver with a cellular energy-sensing one is a rational complementary metabolic pairing.

    Tier 4Theoretical — not established

    Shares mitochondrial function · lipolysis

  • RetatrutideComplementary

    No documented conflict

    MOTS-c is a mitochondrial-derived peptide that activates AMPK, improves insulin sensitivity and promotes fat oxidation/adipose browning — a metabolic mechanism entirely separate from retatrutide's gut-hormone receptors. Both push toward improved glucose handling and fat loss, so they complement each other on the same metabolic goal via different pathways.

    Tier 4Theoretical — not established

    Shares lipolysis

  • BPC-157

    Proposed as compatible, but the two compounds' own mechanism data did not support the pairing.

  • GHK-CuSame downstream effect

    No documented conflict

    GHK-Cu and MOTS-c both blunt inflammation and support mitochondrial antioxidant defenses through separate routes. GHK-Cu activates SIRT1, delivers copper to superoxide dismutase to lower ROS, and suppresses NF-kB and inflammatory cytokines including IL-6, TNF-alpha and IL-1beta. MOTS-c activates AMPK and engages the Keap1-Nrf2/ARE axis to drive a cytoprotective antioxidant stress response. They reach a common antioxidant, anti-inflammatory output from distinct origins, and nothing in their described biology suggests a conflict.

    Tier 4Theoretical — not established

    Shares anti inflammatory · mitochondrial function

  • EpithalonComplementary

    No documented conflict

    Both are longevity-oriented peptides converging on antioxidant defense and metabolic/mitochondrial health via distinct mechanisms — MOTS-c drives AMPK/PGC-1α mitochondrial biogenesis and NRF2 antioxidant response, while Epithalon works through telomerase, senescence-pathway, and circadian/antioxidant modulation. Complementary geroprotective strategies.

    Tier 4Theoretical — not established
  • Follistatin-344Same downstream effect

    Worth caution

    MOTS-c is reported to regulate myostatin through a CK2-PTEN-mTORC2-AKT-FOXO1 axis, converging on the same muscle-limiting signal that Follistatin neutralizes directly. Both also add metabolic/anti-inflammatory benefits, so they may reinforce each other on body composition, though this convergence is only weakly characterized.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Follistatin-344 acts directly on myostatin/GDF-8, sequestering the ligand and blocking SMAD2/3 signaling; MOTS-c has no comparable direct action, and its influence on myostatin—if any—would be indirect via a CK2-PTEN-mTORC2-AKT-FOXO1 route that is not established as a primary mechanism. Their anti-inflammatory effects also arise through different pathways (TGF-beta antagonism versus Keap1-Nrf2 and AMPK), so a shared muscle-limiting target is not demonstrated.

    Shares anti inflammatory

  • AOD-9604Complementary

    May be complementary

    MOTS-c improves fat metabolism and drives fat oxidation/adipose browning via AMPK and mitochondrial signaling, while AOD-9604 mobilizes fat by raising cAMP and activating hormone-sensitive lipase. Mobilization (AOD) plus enhanced oxidation (MOTS-c) are logically complementary steps of the same fat-loss process.

    Tier 4Theoretical — not established

    Shares lipolysis

  • HumaninComplementary

    May be complementary

    Both humanin and MOTS-c are mitochondrial-derived peptides ('mitokines') that signal cellular stress and improve metabolism, but they work through different downstream routes — humanin is chiefly cytoprotective/anti-apoptotic (Bax inhibition, STAT3, PI3K/Akt) while MOTS-c drives AMPK activation and Nrf2 antioxidant responses. Together they cover complementary arms of the same mitochondrial-stress response, which is why they are often discussed as a metabolic/longevity pairing.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory

  • KlothoComplementary

    May be complementary

    Klotho and MOTS-c hit overlapping anti-aging endpoints by different mechanisms. Klotho activates the Nrf2 and FoxO antioxidant programs and suppresses TGF-β/Smad fibrosis and NLRP3 inflammation; MOTS-c is a mitochondrial peptide that activates AMPK and the Keap1-Nrf2 antioxidant axis, improves insulin sensitivity, and also blunts TGF-β1/Smad fibrosis. The shared antioxidant, antifibrotic and insulin-sensitizing outputs make them logically complementary.

    Tier 4Theoretical — not established

    Shares anti inflammatory

Safety and side effects

Safety overview

Safety data in humans are limited and come mainly from a MOTS-c analog. CohBar reports1 that CB4211 was well-tolerated and appeared safe with no serious adverse events in its Phase 1a/1b study. The ADDF review17 states MOTS-c's therapeutic safety has not been established, that CB4211 was safe in a short-term study but persistent injection-site reactions were common, and that MOTS-c may interact with other drugs targeting AMPK. A 2025 preprint22 and a 2025 review21 both note human safety and efficacy data are scarce;21 warns of potential for serious harm and notes MOTS-c operates in a parallel gray market largely outside regulatory oversight.

Reported side effects

A vendor resource states MOTS-c side effects include mild, transient injection-site reactions, and uncommonly headache and mild fatigue or flu-like symptoms during initial doses(vendor claim).

Precautions and contraindications

  • The vendor resource states MOTS-c can cause blood-glucose changes, so monitoring is recommended for diabetics, and that improved insulin sensitivity can drive blood sugar too low when combined with glucose-lowering medications(vendor claim). It lists pregnancy and breastfeeding as absolute contraindications.
  • The 2025 preprint22 notes ME/CFS patients often experience heightened drug sensitivities and paradoxical reactions, attributed to mitochondrial dysfunction, altered detoxification and potential cytochrome P450 polymorphisms.
  • A 2024 study8 reports MOTS-c showed anti-tumor effects without systemic toxicity in vivo (animal data).

Contested inflammation signal

Most sources describe MOTS-c as anti-inflammatory and antioxidant16,17,22. However, a 2018 review3 reports MOTS-c exacerbates the senescence-associated secretory phenotype (SASP) in senescent cells by stimulating secretion of IL-6, IL-1β, IL-8, IL-10 and TNF-α — a nuance that conflicts with the predominant anti-inflammatory framing.

Regulatory and sport status

Multiple sources note MOTS-c is not FDA-approved for any medical or wellness purpose18. A clinic press article18 reports a split FDA Pharmacy Compounding Advisory Committee vote (7-5 with two abstentions) regarding possible inclusion of MOTS-c-related substances on the 503A Bulks List. The dosing website states WADA bans MOTS-c at all times(vendor claim). A peptide blog states clinical use remains experimental and that injection should only occur under medical supervision(vendor claim).

Reconstitution and handling

Dosing

No dose has been established for native MOTS-c. No regulatory label exists for it, and multiple sources state it is not FDA-approved and that no method of clinical application has been developed11,18. The figures below are what sources report — not guidance — and sources do not reconcile with one another.

  • A vendor resource describes subcutaneous injection at 5–10 mg per dose, 2–3 times weekly(vendor claim).
  • A dosing-protocol website (tier 3) reports common research planning of 5 mg subcutaneously, 2–3 times per week, for 4–8 weeks(vendor claim). It states smaller, more frequent doses are described as a way to keep AMPK signaling steadier given MOTS-c's short estimated half-life, and that larger weekly totals do not appear to add benefit in published animal work and may increase side effects. The same source notes none of these protocols have been validated in a published human randomized trial, no published human trial has compared cycle lengths directly, and the tiers are summarized from animal studies (Reynolds 2021, Lee 2015, Kumagai 2021).
  • A clinic analysis notes animal research typically uses 5 mg/kg daily in rodents (direct bodyweight extrapolation to a human dose is not a valid scaling method and is not a proposed human dose), while practical protocols suggest much lower doses of 5–10 mg total per injection(vendor claim).
  • The only human dosing figure comes from CohBar's trial of the analog CB42111, which used 25 mg once daily.

These ranges — 5–10 mg total per injection and 25 mg/day of an analog — are large discrepancies, and the low doses have not been validated in published human trials.

Reconstitution arithmetic

The dosing website describes reconstituting a 10 mg vial with 1.0 mL bacteriostatic water, which yields a concentration such that a 5 mg dose equals 0.5 mL, or 50 units on a U-100 insulin syringe(vendor claim). This is a calculation about the vial's concentration, not a dosing recommendation.

Administration route

Human/practitioner protocols describe subcutaneous injection25. In animal work, intraperitoneal injection is used6,10. For cognitive endpoints specifically, the ADDF review17 notes peripheral administration was ineffective in mice and that MOTS-c is not blood-brain-barrier penetrant, with effects seen only via intracerebroventricular or carrier-coupled intranasal delivery.

Sources

Ordered by evidence quality — the strongest first.

  1. Nonalcoholic Fatty Liver Disease Clinical Trial(opens in a new tab)
    Tier 1Web · cohbar.com
  2. Effects of Mitochondrial-Derived Peptides (MDPs) on Mitochondrial and Cellular Health in AMD(opens in a new tab)
    Tier 1Web · doi.org · 2020
  3. Mitochondrial-Derived Peptides Exacerbate Senescence.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  4. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2015
  5. MOTS-c: A promising mitochondrial-derived peptide for ... - PMC(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  6. MOTS-c mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3(opens in a new tab)
    Tier 2Web · doi.org · 2025
  7. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  8. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  9. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  10. MOTS-c Functionally Prevents Metabolic Disorders.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  11. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  12. Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c).(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  13. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  14. Mitochondrial-derived peptides and exercise.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  15. MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  16. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  17. MOTS-c(opens in a new tab)
    Tier 3Web · alzdiscovery.org
  18. California Gave the World MOTS-c. Now California Trim Clinic Is Bringing the Conversation Home – News Radio KOTA(opens in a new tab)
    Tier 3Web · lifestyle.kotaradio.com · 2026
  19. Financial News | myMotherLode.com - California Gave the World MOTS-c. Now California Trim Clinic Is Bringing the Conversation Home(opens in a new tab)
    Tier 3Web · money.mymotherlode.com · 2026
  20. FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns(opens in a new tab)
    Tier 3Web · health.com · 2026
  21. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  22. Redefining Mitochondrial Therapy for ME/CFS: The Case for MOTS-c(opens in a new tab)
    Tier 3Web · doi.org · 2025
  23. Exercise-Induced Muscle-Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  24. Mitochondrial Open Reading Frame of the 12S rRNA Type-c: Potential Therapeutic Candidate in Retinal Diseases.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  25. Thời Sự Buổi Sáng | 08/05/2026 | FULL🔴(opens in a new tab)
    Tier 4Web · youtube.com

See something wrong or out of date on this page? Report it.